Atlas Trials

Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

Clinical trial NCT02545361 · WITHDRAWN

Trial details

NCT number
NCT02545361
Sponsor
Kahr Medical
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoma
Start date
2018-04-01
Primary completion
2020-04-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.